Table 3.
Outcomes and results of CAPTEM.
| Primary site, % | Pts (n) | Prior treatment | CAP/TEM dosage (mg/m2) | Results (%) | PFS (months) | Observed toxicities, % |
|---|---|---|---|---|---|---|
| Peixoto et al. [4] | ||||||
| Pancreatic, 48.3 Small bowel, 20.7 Lung, 10.3 Rectum, 6.9 Appendix, 3.4 Unknown, 10.3 |
29 | (i) Octreotide (ii) Local therapy (iii) Chemotherapy (iv) Targeted therapy |
Cap: 750 Tem: 200 |
N/A | 4.7 | N/A |
|
| ||||||
| Fine et al. [5] | ||||||
| Pancreatic, 39 MEN1, 11 Carcinoids, 22.5 Gastrinoma, 11 Glucagonoma, 5.5 Insulinoma, 11 |
18 | (i) Octreotide (ii) Chemotherapy (iii) Chemoembolization |
Cap: 600 Tem: 150–200 |
CR: 6 PR: 56 SD: 22 |
14 | Thrombocytopenia (grade 3 toxicity), 11 Hand-foot syndrome (grade 2), 5.5 Lymphopenia (grade 1/2), 50 Neutropenia (grade 1/2), 44 |
|
| ||||||
| Fine et al. [6] | ||||||
| Pancreatic, 39 Atypical/typical carcinoid, 42.8 Pituitary, 10.7 Thyroid gland, 7 |
28 | (i) Octreotide | Cap: 750 Tem: 150–200 |
CR: 11 PR: 32 SD: 54 PD: 3 |
22 | Lymphopenia (grade 3/4), 32 Hyperglycemia (grade 3/4), 15 Thrombocytopenia (grade 3/4), 3 |
|
| ||||||
| Crespo et al. (abstract only) [7] | ||||||
| Pancreatic, 70.8 | 65 | N/A | N/A | CR: 3 PR: 45 SD: 42 |
16 | Grade 3/4 toxicity, 13.8 Thrombocytopenia, 10.8 Neutropenia, 7.7 |
|
| ||||||
| Strosberg et al. [8] | ||||||
| Pancreatic, 100 | 30 | (i) Octreotide (ii) Local therapy |
Cap: 750 Tem: 200 |
PR: 70 SD: 27 PD: 3 |
18 | Grade 3/4 toxicity, 12 Hand-foot syndrome |
|
| ||||||
| Ramirez et al. [9] | ||||||
| Pancreatic, 52 Small bowel, 31 Lung, 10 Rectal, 7 |
29 | (i) Cytoreduction (ii) Targeted therapy (iii) Radionuclide therapy (iv) Chemotherapy |
Cap: 750 Tem: 200 |
PR: 17 SD: 48 PD: 34 |
12 | Thrombocytopenia grade 1 (3), grade 2 (3), grade 3 (1) Lymphocytopenia grade 1 (3), grade 2 (9), grade 3 (3) Neutropenia (grade 4), 3 Hand-foot syndrome grade 1 (6), grade 2 (3) |
|
| ||||||
| Spada et al. [10] | ||||||
| Pancreatic, 55 GI & unknown, 24 Lung, 21 |
58 | (i) Octreotide (ii) Chemotherapy |
Cap: 1,500 Tem: 150–200 |
PR: 22 SD: 52 PD: 23 |
13 | Thrombocytopenia (grade 3/4) |
|
| ||||||
| Fine et al. [11] | ||||||
| Metastatic NETs | 10 | (i) Octreotide (ii) Chemotherapy |
Cap: 750 Tem: 150–200 |
CR: 16 PR: 34 SD: 50 |
NA | Hand-foot syndrome (grade 3), one case. |
|
| ||||||
| Saif et al. [12] | ||||||
| Pancreatic, 100 | 7 | (i) Octreotide (ii) Local therapy (iii) Chemotherapy |
Cap: 1,000 Tem: 200 |
PR: 43 SD: 28 PD: 29 |
12 | Thrombocytopenia (grade 3), one case. Fatigue (grade 3), one case Neutropenia (grade 1/2) Hand-foot syndrome (grade 1/2) |
|
| ||||||
| Abbasi et al. [13] | ||||||
| Pancreatic Rectum Colon Stomach |
21 | (i) Octreotide (ii) Chemotherapy (iii) Local therapy |
Cap: 600 Tem: 50–200 |
PR: 57 SD: 23 PD: 20 |
17 | No grade 4 toxicity |
|
| ||||||
| Ramirez et al. [14] | ||||||
| Pancreatic, 50 Small bowel, 30 Lung, 13 Rectum, 7 |
30 | N/A | N/A | PR: 33 SD: 40 PD: 27 |
11 | Cytopenia, 25 Hand-foot syndrome, 35 |
N/A: not available, CR: complete response, PR: partial response, SD: stable disease, PD: progressive disease, Cap: capecitabine, and Tem: temozolomide.